Influence of tumour size on uptake of111In-DTPA-labelled pegylated liposomes in a human tumour xenograft model

• Published in: British journal of cancer 2000-09, Vol.83 (5), p.684-688
• Main Authors: Harrington, K J, Rowlinson-Busza, G, Syrigos, K N, Abra, R M, Uster, P S, Peters, A M, Stewart, J S W
• Format: Article
• Language: English
• Subjects: Biomedical and Life Sciences; Biomedicine; Cancer Research; Chemotherapy; Drug Resistance; Epidemiology; Lipids; Localization; Medical research; Molecular Medicine; Oncology; Regular; regular-article; Response rates; Tumors
• ISSN: 0007-0920; 1532-1827
• DOI: 10.1054/bjoc.2000.1320

The relationship between tumour size and uptake of 111 In-DTPA-labelled pegylated liposomes has been examined in a human head and neck cancer xenograft model in nude mice. The mean tumour uptake of 111 In-labelled pegylated liposomes at 24 hours was 7.2 ± 6.6% ID/g. Liposome uptake for tumours < 0.1 g, 0.1–1.0 g and > 1.0 g was 15.1 ± 10.8, 5.9 ± 2.2 and 3.0 ± 1.3% ID/g, respectively. An inverse correlation between tumour weight and liposome uptake was observed by both Spearman’s rank correlation test (r s = – 0.573, P < 0.001) and Pearson’s correlation coefficient (r s = – 0.555, P < 0.001). For 18 tumours with macroscopic central necrosis, the ratio of uptake in the tumour rim relative to the necrotic tumour core was 11.2 ± 6.4. Measurement of tumour vascular volume for tumours of various sizes revealed an inverse correlation between tumour weight and tumour vascular volume (Spearman’s rank correlation test, r s = – 0.598, P < 0.001), consistent with poor or heterogeneous vascularization of larger tumours. These data have important implications for the clinical application of pegylated liposome targeted strategies for solid cancers which are discussed in detail. © 2000 Cancer Research Campaign